(Q46952197)

English

Effects of oral glatiramer acetate on clinical and MRI-monitored disease activity in patients with relapsing multiple sclerosis: a multicentre, double-blind, randomised, placebo-controlled study

scientific article published in March 2006

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/16488376

Effects of oral glatiramer acetate on clinical and MRI-monitored disease activity in patients with relapsing multiple sclerosis: a multicentre, double-blind, randomised, placebo-controlled study (English)

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/16488376

multiple sclerosis

0 references

1 reference

based on heuristic

inferred from title

Massimo Filippi

object named as

Massimo Filippi

1

0 references

3

object named as

Giancarlo Comi

1 reference

Europe PubMed Central

26 December 2017

Jerry S Wolinsky

2

object named as

Jerry S Wolinsky

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/16488376

author name string

CORAL Study Group

4

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/16488376

publication date

1 March 2006

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/16488376

Lancet Neurology

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/16488376

5

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/16488376

3

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/16488376

213-220

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/16488376

A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970327-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970327-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970327-1

7 January 2021

based on heuristic

inferred from DOI database lookup

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970327-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes".

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970327-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of glatiramer acetate on relapse rate and accumulated disability in multiple sclerosis: meta-analysis of three double-blind, randomized, placebo-controlled clinical trials.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970327-1

7 January 2021

based on heuristic

inferred from DOI database lookup

The distribution of the magnetic resonance imaging response to glatiramer acetate in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970327-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970327-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Multiple sclerosis: comparison of copolymer-1- reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970327-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Glatiramer acetate in multiple sclerosis: update on potential mechanisms of action

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970327-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Glatiramer acetate for the treatment of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970327-1

7 January 2021

based on heuristic

inferred from DOI database lookup

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970327-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970327-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Intra-observer reproducibility in measuring new putative MR markers of demyelination and axonal loss in multiple sclerosis: a comparison with conventional T2-weighted images

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970327-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Short-term brain volume change in relapsing-remitting multiple sclerosis: effect of glatiramer acetate and implications

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970327-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Immunologic mechanisms and therapy in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970327-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Multiple sclerosis is not an autoimmune disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970327-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1474-4422(06)70327-1

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/16488376

1 reference

Europe PubMed Central

26 December 2017

http://europepmc.org/abstract/MED/16488376

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46952197&oldid=2139476555"